Capecitabine in the Treatment of Advanced Gastric Cancer

Jae-Lyun Lee; Yoon-Koo Kang


Future Oncol. 2008;4(2):179-198. 

In This Article


For patients with AGC, the main treatment option is systemic chemotherapy, which could improve the quantity and quality of life. Although a number of randomized Phase III trials have been performed to determine the most appropriate regimen for these patients, no internationally accepted standard chemotherapeutic regimen currently exists. Orally available capecitabine has been shown in Phase III trials to be more convenient and safe, and possibly more effective, than infusional 5-FU. Therefore, capecitabine should become the fluoropyrimidine of choice for AGC patients, as well as being a platform for new drug combinations. The capecitabine-based doublet, XP, and triplets, EOX and DXP, are active and well tolerated as first-line treatment in patients with AGC. However, considering the modest benefit in OS, more effective chemotherapy regimens, incorporating newer cytotoxic or molecular-targeted biologics, are needed.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.